Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance.
暂无分享,去创建一个
[1] J. Rothberg,et al. HIGH-THROUGHPUT, MASSIVELY PARALLEL DNA SEQUENCING TECHNOLOGY FOR THE ERA OF PERSONALIZED MEDICINE , 2007 .
[2] Fangping Cai,et al. Detection of minor drug-resistant populations by parallel allele-specific sequencing , 2007, Nature Methods.
[3] Ingrid A. Beck,et al. Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency , 2006, Journal of Clinical Microbiology.
[4] Thomas LaFramboise,et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.
[5] J. Mellors,et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[6] Sarah Palmer,et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy , 2006, AIDS.
[7] L. Loeb,et al. The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[8] G. Tsongalis,et al. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[9] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[10] M. Moser,et al. Quantifying Mixed Populations of Drug-Resistant Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.
[11] J. Strathern,et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. , 2005, The Journal of infectious diseases.
[12] W. Heneine,et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. , 2005, The Journal of infectious diseases.
[13] M. Ronaghi,et al. Genetic variation analyses by Pyrosequencing. , 2005, Mutation research.
[14] R. Shafer,et al. Detection of Minority Populations of HIV-1 Expressing the K103N Resistance Mutation in Patients Failing Nevirapine , 2005, Journal of acquired immune deficiency syndromes.
[15] John W. Mellors,et al. Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.
[16] Ingrid A. Beck,et al. Comparison of Oligonucleotide Ligation Assay and Consensus Sequencing for Detection of Drug-Resistant Mutants of Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells and Plasma , 2004, Journal of Clinical Microbiology.
[17] S. Hammer,et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. , 2004, The New England journal of medicine.
[18] R. Shafer,et al. Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay , 2004, Journal of Virology.
[19] J. Shendure,et al. Advanced sequencing technologies: methods and goals , 2004, Nature Reviews Genetics.
[20] K. Metzner,et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.
[21] H. Agut,et al. From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. , 2003, Journal of virological methods.
[22] Jacques Izopet,et al. Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.
[23] B. Larder,et al. Performance of the Affymetrix GeneChip HIV PRT 440 Platform for Antiretroviral Drug Resistance Genotyping of Human Immunodeficiency Virus Type 1 Clades and Viral Isolates with Length Polymorphisms , 1999, Journal of Clinical Microbiology.
[24] D. Nickerson,et al. Oligonucleotide Ligation Assay for Detecting Mutations in the Human Immunodeficiency Virus Type 1 polGene That Are Associated with Resistance to Zidovudine, Didanosine, and Lamivudine , 1998, Journal of Clinical Microbiology.
[25] T. Merigan,et al. Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma , 1997, Journal of clinical microbiology.
[26] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.